Skip to content

Evaluating the effect of Acetazolamide on the prevention of post-operative Acute Kidney Injury following Coronary Artery Bypass Grafting surgery

Evaluating the effect of Acetazolamide on the prevention of post-operative Acute Kidney Injury (AKI) following Coronary Artery Bypass Grafting (CABG) surgery

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151227025726N21
Enrollment
70
Registered
2020-09-17
Start date
2020-03-19
Completion date
Unknown
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury. Acute kidney injury

Interventions

Intervention 1: Intervention group: Patients in the acetazolamide group are treated with acetazolamide at a dose of 500 mg once daily on the morning of surgery. Intervention 2: Control group: Patients

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: It will be performed on patients who refer to Masih Daneshvari and Modares Hospital for Coronary Artery Bypass Surgery (CABG).

Exclusion criteria

Exclusion criteria: History of any allergies to any of the compounds in acetazolamide tablets and sulfonamide compounds Liver failure (stage II, III or liver enzymes more than 3 times) Chronic renal failure (Stage IV & V CKD) or patients with serum creatinine less than 30 ml / min, anorexia Chronic heart failure (Ejection Fraction <30) Patients undergoing CABG surgery for emergency reasons. Hypokalemia (potassium less than 3.3 mmol / L), hyponatremia (sodium less than 135 mmol / L) Gout attack

Design outcomes

Primary

MeasureTime frame
Creatinine plasma LEVEL. Timepoint: Before surgery and daily for up to seven days. Method of measurement: ELISA.;Volume of urine. Timepoint: Before the operation until the patient is in the intensive care unit. Method of measurement: The amount of urine in the urine bag.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolnaz Afzal

Shahid Beheshti University of Medical Sciences

Pr_pharmacy@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026